The AIM-listed immunotherapy specialist will present three posters at the AAAAI Annual Meeting in Philadelphia this week
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF, FRA:HHU), the AIM-listed biotechnology company specialising in allergy treatments, said it would present positive clinical and safety data from across its research portfolio at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Philadelphia.
The company's flagship grass pollen treatment, Grass MATA MPL, delivered a statistically significant 22.5% improvement in a combined symptom and medication score compared with placebo across two phase III clinical trials.
The data showed the short-course injectable treatment effectively modulated both humoral and cellular immune responses, supporting its use as a treatment for seasonal allergic rhinitis, commonly known as hay fever.
Separately, the company presented short-term safety data from the first group of 190 children and adolescents enrolled in a Phase III trial investigating the same treatment in younger patients, reporting a benign safety profile and low dropout rate.
Allergy Therapeutics also shared early-stage data from its VLP Peanut programme, a novel short-course peanut allergy immunotherapy candidate currently in a Phase I/IIa trial in healthy and peanut-allergic adults.
The company said interim results confirmed the treatment's safety and tolerability, describing it as a promising candidate for peanut allergy.
Manuel Llobet, chief executive, said the three presentations reflected the breadth of the company's clinical portfolio and described the data as another step in its mission to deliver disease-modifying therapies for allergy sufferers.
The AAAAI conference, which runs from 27 February to 2 March, is considered one of the leading gatherings in the allergy and immunology field, attracting more than 7,000 specialists worldwide.
Grass MATA MPL recently received regulatory approval in Germany, becoming the first subcutaneous grass pollen immunotherapy to be authorised under the country's Therapy Allergen Ordinance (TAV) framework.